Compounds > idarubicin
Page last updated: 2024-08-23

idarubicin and Carcinoma, Epidermoid

idarubicin has been researched along with Carcinoma, Epidermoid in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Holpuch, AS; Hummel, GJ; Ma, P; Mallery, SR; Mumper, RJ; Pei, P; Seghi, GA; Tong, M1
McKenna, KE; Morris, TC; Ramadan, KM1
Alberto, P; Cavalli, F; Joss, RA; Obrecht, JP; Siegenthaler, P; VanHelvoirt, A1
Dekker, H; Lankelma, J; Mülder, HS; Pinedo, HM1
Burke, TW; Eifel, PJ; Gabel, C; Tornos, C1

Reviews

1 review(s) available for idarubicin and Carcinoma, Epidermoid

ArticleYear
Radiation recall reaction to idarubicin resulting in vaginal necrosis.
    Gynecologic oncology, 1995, Volume: 57, Issue:2

    Topics: Carcinoma, Squamous Cell; Female; Humans; Idarubicin; Middle Aged; Necrosis; Radiotherapy; Time Factors; Vaginal Diseases; Vaginal Neoplasms; Vulvitis

1995

Other Studies

4 other study(ies) available for idarubicin and Carcinoma, Epidermoid

ArticleYear
Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies.
    Pharmaceutical research, 2010, Volume: 27, Issue:7

    Topics: Antibiotics, Antineoplastic; Blotting, Western; Boron Compounds; Carcinoma, Squamous Cell; Cells, Cultured; Drug Delivery Systems; Fluorescent Dyes; Humans; Idarubicin; Immunohistochemistry; Mouth Mucosa; Nanoparticles

2010
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
    The Lancet. Oncology, 2006, Volume: 7, Issue:11

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid

2006
Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
    Cancer treatment reports, 1984, Volume: 68, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Daunorubicin; Digestive System; Drug Evaluation; Heart; Humans; Idarubicin; Leukopenia; Lung Neoplasms; Middle Aged

1984
The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
    Biochemical pharmacology, 1995, Sep-28, Volume: 50, Issue:7

    Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Death; Cell Membrane Permeability; Chromatography, High Pressure Liquid; Cytosol; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Surface-Active Agents; Tumor Cells, Cultured

1995